Clinical Operations
Clinical Project ManagementStudy Monitoring and Site ManagementTrial Master File and Document ManagementQuality and Vendor Management SystemsStudy DocumentsRegulatory Affairs
Regulatory StrategyRegulatory WritingAgency Communications and SubmissionsDocument Editorial, QC and SubmissionQC, Review and RedactionLegal RepresentationPharmacovigilanceILAP SubmissionsMedical Communications
Publication PlanningStrategic CommunicationsScientific CommunicationsMedical EducationMedical IllustrationGrant Applications and Project PartnershipNiche's skilled medical writing team engaged with ViiV Healthcare to quickly and efficiently develop high quality documents to support their global outreach activities. This involved:
ViiV Healthcare is a global specialist company majority owned by GSK, with Pfizer and Shionogi as shareholders. ViiV is exclusively committed to HIV medicines and research, focusing on people living with HIV and AIDS. The company was established with one ambitious, clear goal: to end the HIV epidemic. In addition to exploring new ways to treat, prevent and ultimately find a cure for HIV, they are focusing on understanding how to bridge the gap between research and everyday clinical practice. ViiV’s pipeline is centred on integrase inhibitors, with a variety of other compounds, including broadly neutralising antibodies and capsid inhibitors. To date, their portfolio consists of 17 prescription medicines. Alongside R&D, ViiV is committed to improving access to HIV medicines and community initiatives that strengthen local healthcare services for people living with HIV.
Niche and ViiV have had a longstanding collaboration, continuing from support provided to GSK's award winning Positive Action patient advocacy programme. Niche was invited to provide editorial and medical writing services to ViiV’s partner organisations involved in patient outreach programmes. In addition, ViiV also relied on Niche’s strategic input on various regulatory and medical affairs projects.
From very early on, ViiV’s specialist clinical ambitions were well served by Niche’s deep clinical expertise and patient-centric approach. The Niche team recognises that patient care should be paramount at every stage of clinical development. This ethos synergised well with ViiV’s patient outreach programmes.
ViiV faced major challenges in providing global access of essential medications to people living with HIV. Thus, ViiV deployed Niche’s research competencies to inform their global medications access and regulatory strategies. The team’s extensive experience in literature searches meant that they could quickly and flexibly provide ViiV with relevant information, appropriately targeted to their regulatory requirements.